{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:06:03Z","timestamp":1788815163351,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Angiotensin converting enzyme inhibitors (ACEI) have proven mortality and morbidity benefit in hypertension, ischemic heart disease, heart failure, and renal disease and are among the most prescribed medications globally. ACEI angioedema (AE-ACEI) is a potentially life-threatening adverse drug reaction that is reported to occur more frequently in African American populations. However, the clinical profile of AE-ACEI is poorly characterized in diverse African populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A case-controlled cohort study with enrolment of AE-ACEI cases and drug-tolerant controls in Cape Town, South Africa. Univariable and multivariable analysis was performed. Controls were defined as patients tolerating ACEI for a minimum of two years. Cases were defined as patients who had angioedema while using an ACEI, patients with a history of angioedema while not on an ACEI were excluded. Cases and controls were recruited from the same demographic areas, including both hospitals and clinics. Information regarding demographics and clinical history was captured via both in person interviews and folder review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 237 AE-ACEI cases, and 466 ACEI tolerant controls were enrolled from seven sites in Cape Town. Features of IgE-mediated immediate drug hypersensitivity were present in 24 cases, which excluded them from analysis. The median age was 58 years (IQR: 47; 67) and 57% were female. AE-ACEI cases more frequently had Black genetic ancestry compared to controls [53% (81\/154), vs. 29% (146\/407), <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001]. AE-ACEI occurred within 30 days of initiating ACEI therapy in only 31.1% (70\/225), with median treatment time to AE-ACEI of 6.9 years (IQR: 2.9; 13). The ACEI tolerant controls were using ACEI for median 9.5 years (IQR: 5; 15.5). All AE-ACEI cases developed swelling above the shoulders, involving the lips and tongue in 72% (165\/213) and 50% (107\/213) cases respectively. Hospitalisation for AE-ACEI was required in 82% (175\/213), however only two patients were intubated, and there were no mortalities. In multivariable analysis traditional risk factors of age, gender, immunosuppression and atopy did not differ between cases and controls. Black genetic ancestry [aOR 15.4 (95% CI 2.94\u2013283), <jats:italic>p<\/jats:italic> value\u2009=\u20090.01] and calcium channel blocker use [aOR 1.77 (95% CI 1.17\u20132.72), <jats:italic>p<\/jats:italic> value\u2009=\u20090.008] were significant risk factors for developing AE-ACEI. Cardiac failure, chronic kidney disease, and statin use reduced the risk of AE-ACEI in this model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this South African population, Black genetic ancestry and calcium channel blocker use were the major risk factors for AE-ACEI. The majority of AE-ACEI occurred after several years of treatment, with most cases involving the lip and\/or tongue. Long-term follow-up, genetic, and further mechanistic studies are warranted in additional diverse African populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1664354","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:22:54Z","timestamp":1760937774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population"],"prefix":"10.3389","volume":"6","author":[{"given":"Cascia","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovemore","family":"Mapahla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Deetlefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelein","family":"Engelbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJM198812083192305","article-title":"Converting-enzyme inhibitors in the treatment of hypertension","volume":"319","author":"Williams","year":"1988","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Swedberg","year":"1987","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0140-6736(93)92693-N","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e54311","DOI":"10.7759\/cureus.54311","article-title":"A comparative study of the safety and efficacy between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the management of hypertension: a systematic review","volume":"16","author":"Peresuodei","year":"2024","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-021-08841-w","article-title":"Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs. Mast cell-mediated angioedema","volume":"61","author":"Maurer","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7196\/SAMJ.2023.v113i8.717","article-title":"Acute angioedema in Cape Town emergency centres and a suggested algorithm to simplify and improve management","volume":"113","author":"Day","year":"2023","journal-title":"S Afr Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2222.2009.03323.x","article-title":"Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors","volume":"40","author":"Hoover","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1081-1206(10)60267-0","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department","volume":"103","author":"Bluestein","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0003489414543069","article-title":"Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management","volume":"124","author":"Chan","year":"2015","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1503\/cmaj.060535","article-title":"Angioedema without urticaria: a large clinical survey","volume":"175","author":"Zingale","year":"2006","journal-title":"Can Med Assoc J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s001340050413","article-title":"Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome","volume":"23","author":"Agah","year":"1997","journal-title":"Intensive Care Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/lary.25821","article-title":"Case-control study evaluating competing risk factors for angioedema in a high-risk population","volume":"126","author":"Kamil","year":"2016","journal-title":"Laryngoscope"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/pds.4260","article-title":"Antihypertensive drug associated angioedema: effect modification by race\/ethnicity","volume":"26","author":"Reichman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","article-title":"Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema","volume":"60","author":"Brown","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/000348940111000906","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter review and an algorithm for airway management","volume":"110","author":"Chiu","year":"2001","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.anai.2021.07.028","article-title":"Incidence and risk factors of angiotensin-converting enzyme inhibitor-induced angioedema: a large case-control study","volume":"127","author":"Garcia-Saucedo","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK clinical practice research datalink","volume":"82","author":"Mahmoudpour","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2500\/ajra.2014.28.3989","article-title":"Life-threatening angioedema induced by angiotensin-converting enzyme inhibitors: characteristics and risk factors","volume":"28","author":"Stauber","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J Eval Clin Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1060028016682251","article-title":"Comparison of clinical factors between patients with angiotensin-converting enzyme inhibitor-induced angioedema and cough","volume":"51","author":"Hallberg","year":"2017","journal-title":"Ann Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1398-9995.2010.02398.x","article-title":"Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use","volume":"65","author":"Byrd","year":"2010","journal-title":"Allergy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/509899","article-title":"Increased activity of coagulation factor XII (hageman factor) causes hereditary angioedema type III","volume":"79","author":"Cichon","year":"2006","journal-title":"Am J Hum Genet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S1081-1206(10)60584-4","article-title":"Hereditary angiodema: a current state-of-the-art review, VII: canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema","volume":"100","author":"Bowen","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","article-title":"Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema","volume":"51","author":"Byrd","year":"2008","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1081-1206(10)62723-8","article-title":"Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients","volume":"82","author":"Abbosh","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1288\/00005537-199203000-00005","article-title":"Angioedema: 5 years\u2019 experience, with a review of the disorder\u2019s presentation and treatment","volume":"102","author":"Megerian","year":"1992","journal-title":"Laryngoscope"},{"key":"B32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00002018-199818030-00003","article-title":"ACE inhibitor-induced angioedema. Incidence, prevention and management","volume":"18","author":"Vleeming","year":"1998","journal-title":"Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1398-9995.1997.tb01024.x","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers","volume":"52","author":"Schiller","year":"1997","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.anai.2013.11.016","article-title":"Evaluating for seasonal variation in angiotensin-converting enzyme inhibitor- and angiotensin receptor blocker-induced angioedema","volume":"112","author":"Wilson","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaip.2013.05.003","article-title":"Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema","volume":"1","author":"Straka","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/20009666.2019.1698259","article-title":"Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients","volume":"9","author":"Pfaue","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/bmj.304.6832.941","article-title":"Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors","volume":"304","author":"Hedner","year":"1992","journal-title":"Br Med J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.12932\/AP0556.33.3.2015","article-title":"Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai national pharmacovigilance database","volume":"33","author":"Win","year":"2015","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"Br Med J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/pgs-2016-0184","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population","volume":"18","author":"Hallberg","year":"2017","journal-title":"Pharmacogenomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.23889\/ijpds.v4i2.1143","article-title":"Data centre profile: the provincial health data centre of the Western Cape Province, South Africa","volume":"4","author":"Boulle","year":"2019","journal-title":"Int J Popul Data Sci"},{"key":"B44","volume-title":"Release Fifteen","year":"2017"},{"key":"B45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.18176\/jiaci.0087","article-title":"Novelties in the diagnosis and treatment of angioedema","volume":"26","author":"Cicardi","year":"2016","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/lary.26336","article-title":"The burden of angioedema on United States emergency departments: 2006\u20132010","volume":"127","author":"Smith","year":"2017","journal-title":"Laryngoscope"},{"key":"B47","doi-asserted-by":"publisher","first-page":"100464","DOI":"10.1016\/j.jacig.2025.100464","article-title":"A GWAS of angiotensin-converting enzyme inhibitor-induced angioedema in a South African population","volume":"4","author":"Mugo","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B48","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1161\/CIRCULATIONAHA.123.065887","article-title":"Are recommendations that favor other agents over angiotensin-converting enzyme inhibitors in Africans with hypertension justified?","volume":"149","author":"Peter","year":"2024","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101037","DOI":"10.1016\/j.waojou.2025.101037","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema: proposal for a diagnostic score","volume":"18","author":"Bocquet","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B50","first-page":"148","article-title":"The South African ACARE centre approach to recurrent angioedema without urticaria","volume":"36","author":"Day","year":"2023","journal-title":"Curr Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1046\/j.1365-2133.2003.05090.x","article-title":"Pattern analysis of human cutaneous mast cell populations by total body surface mapping","volume":"148","author":"Weber","year":"2003","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"100809","DOI":"10.1016\/j.waojou.2023.100809","article-title":"Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"16","author":"Douillard","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.gloepi.2021.100063","article-title":"Rising prevalence, and improved but suboptimal management, of hypertension in South Africa: a comparison of two national surveys","volume":"3","author":"Peer","year":"2021","journal-title":"Glob Epidemiol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1664354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:22:55Z","timestamp":1760937775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1664354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":53,"alternative-id":["10.3389\/falgy.2025.1664354"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1664354","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1664354"}}